What is the most recent earnings date for PRME stock?
PRIME MEDICINE INC (PRME) last reported earnings on 3/3/2026.
NASDAQ:PRME • US74168J1016
Past quarterly earnings results for PRIME MEDICINE INC (PRME), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.26 | -0.26 | -1.38% | 16.13% | 838K | 2.387M | -64.89% | -61.61% |
| Q3 2025 | -0.32 | -0.26 | -24.00% | 27.27% | 1.225M | 1.047M | 17.00% | 486.12% |
| Q2 2025 | -0.41 | -0.37 | -10.55% | 10.87% | 1.115M | 1.53M | -27.12% | - |
| Q1 2025 | -0.40 | -0.33 | -22.51% | 9.09% | 1.454M | 1.07M | 35.89% | 146.02% |
| Q4 2024 | -0.31 | -0.40 | 22.47% | 56.94% | 2.183M | 293.25K | 644.42% | - |
| Q3 2024 | -0.44 | -0.40 | -9.16% | 20.00% | 209K | 7.987M | -97.38% | - |
| Q2 2024 | -0.46 | -0.41 | -11.84% | 2.13% | 1.663M | -100.00% | - | |
| Q1 2024 | -0.44 | -0.48 | 8.86% | - | 591K | 165.75K | 256.56% | - |
| Q4 2023 | -0.72 | -0.52 | -38.48% | -28.57% | - | - | ||
| Q3 2023 | -0.55 | -0.47 | -17.22% | - | - | - | ||
| Q2 2023 | -0.47 | -0.43 | -8.85% | - | - | - | ||
| Q1 2023 | -0.44 | -0.42 | -4.20% | - | - | - | ||
| Q4 2022 | -0.56 | -0.67 | 15.86% | - | - | - | ||
| Q3 2022 | - | - | - | - | ||||
| Q2 2022 | - | - | - | - | ||||
| Q1 2022 | - | - | - | - | ||||
| Q4 2021 | - | - | - | - | ||||
| Q3 2021 | - | - | - | - | ||||
| Q2 2021 | - | - | - | - | ||||
| Q1 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - |
Notes
PRIME MEDICINE INC (PRME) last reported earnings on 3/3/2026.
PRIME MEDICINE INC (PRME) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, PRIME MEDICINE INC (PRME) has beaten EPS estimates in 0 out of 4 releases.